EJC Skin Cancer
Издатель: Elsevier · ISSN 2772-6118 · 85 статей
- A-632 - Investigating alterations in autophagy signalling during development and progression of cutaneous Squamous Cell Carcinoma
- A-377 - Management of challenging tumors in a patient diagnosed with oculocutaneous albinism IB
- A-420 - Peritumoral mutant clonal landscapes suggest clonal interactions during cutaneous squamous cell carcinoma development
- A-657 - Predictors of clinical and pathological response in patients with basal cell carcinoma treated with BO-112, a novel intralesional treatment
- A-255 - Psoriasis-like disease prevents squamous skin tumor development by neutrophil-driven inflammation
- A-605 - Q-2361 Reverses Tacrolimus-Induced Carcinogenic Transformation of Keratinocytes: A Novel Prevention Strategy for Squamous Cell Carcinoma in Transplant Recipients.
- A-360 - Relationship between efficacy and cosmetic outcome in tirbanibulin-treated patients with actinic keratosis over a field up to 100 cm²: subanalysis from TirbAKare study
- A-374 - Sequential keratolytic pretreatment enhances tirbanibulin efficacy in field cancerization assessed by line-field confocal optical coherence tomography: a pilot study
- A-534 - Stromal reprogramming in high-risk cutaneous squamous cell carcinoma
- A-517 - The prognostic significance of STING expression in extramammary Paget's disease
- A-353 - Transdermal Delivery of 5-Fluorouracil via Nanoparticle-Infused Microneedles: A Pre-Clinical Study in Superficial Basal Cell Carcinoma
- Cryotherapy for actinic keratoses: A cross-sectional survey of real-world clinical practice
- Neutropenia induced by dabrafenib and trametinib combination therapy in patients with melanoma: Incidence, risk factors and clinical implications
- Title: diagnostic performance of FotoFinder AIMEE in routine specialist dermatology practice
- Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study
- Switch to every-other-day sonidegib dose reduction schedule in advanced basal cell carcinoma: a multicenter retrospective observational study on effectiveness and safety
- Long-term outcomes of cutaneous basal cell and squamous cell carcinomas with < 1 mm close primary surgical excision margins managed in a UK tertiary centre multidisciplinary team
- BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter study
- Comparative analysis of progression free survival and treatment maintenance in patients with advanced melanoma responding to first-line treatment
- Validation of a prognostic microRNA signature in early-stage melanoma across NanoString and RNA-sequencing platforms
- PD-L1 assessment in Merkel cell carcinoma: Predictive implications for anti-PD-1 and anti-PD-L1 therapy
- 10-years of first-line ipilimumab and nivolumab in the management of melanoma brain metastases: a single centre experience
- Immune-related pneumonitis: A retrospective analysis of corticosteroid requirements and the role of hydroxychloroquine in melanoma patients
- The recurrence rate of malignant melanoma treated with staged micrographic excision in South Africa: A retrospective study
- Dermatofibrosarcoma protuberans in South Africa: Outcomes of staged excision and peripheral and deep en face margin assessment (PDEMA) and recommendations for wide local excision margins
- A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial
- Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment
- Living with advanced or metastatic melanoma: A patient-driven conceptual model
- From immune activation to pathological response: neoadjuvant immunotherapy in cutaneous squamous cell carcinoma. A systematic review and meta-analysis
- Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced cutaneous squamous cell carcinoma